[Edaily JAEMIN SONG Choi Oh-hyun Reporter] “We are currently negotiating 2027 HBM prices with our customers, and the discussions are proceeding smoothly. HBM is a product that requires more wafers, advanced manufacturing processes, and significant production resources compared to standard DRAM. We determine prices by comprehensively considering not only standard DRAM prices but also the resources invested, opportunity costs, technical complexity, and the value the product provides to customers. We will maintain robust profitability based on our accumulated technology, cost competitiveness, stable mass production capabilities, and the trust and close cooperation of our customers.”
…SK hynix Q2 2026 Conference Call
A view of SK hynix’s headquarters in Icheon, Gyeonggi Province. (Photo: Yonhap News)
“Regulations on the 52-hour workweek should be relaxed for businesses that create new concepts or for semiconductor research and development (R&D).”KoreaInformation&Communication Technology Promotion …
Ingenia Therapeutics (hereinafter “Ingenia”), a developer of new antibody drugs for microvascular diseases set to list on the KOSDAQ market on the 18th, is expected to show steep growth following a re…
Royvant is focusing its funding and development capabilities on IMVT-1402 (active ingredient: imeropruvate), a next-generation FcRn antibody licensed from HANALL BIOPHARMA CO.,LTD(009420). This comes …